ReviewMicroorganisms2022
CRISPR-Cas Genome Editing Technique for Fish Disease Management: Current Study and Future Perspective.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- The multifaceted challenge of viral nervous necrosis in fish farming: a review of current knowledge and control.Veterinary research communications · 2026Review
- Antibacterial Activity, Phytochemical Composition, and Cytotoxicity Evaluation of Select Medicinal Plants from Bangladesh.Current microbiology · 2025Article
- Charting the Future: Advanced Technologies for Sustainable Parasite Control in Aquaculture.International journal of molecular sciences · 2025Review
- Review
- The role of microbiota in fish spoilage: biochemical mechanisms and innovative preservation strategies.Antonie van Leeuwenhoek · 2025Review
- Host-Parasite Interactions and Integrated Management Strategies for Ecytonucleospora Hepatopenaei Infection in Shrimp.Acta parasitologica · 2025Review
- Advances in nanomaterial-mediated CRISPR/Cas delivery: from lipid nanoparticles to vesicle-derived systems.Frontiers in bioengineering and biotechnology · 2025Review
- Genome editing of WSSV CRISPR/Cas9 and immune activation extends the survival of infected Penaeus vannamei.Scientific reports · 2024Article
- Fish diversity assessment through conventional morphological identification and recent advances in Saudi Arabia: A review.Veterinary world · 2024Review
- CRISPR/Cas9 Technology for Enhancing Desirable Traits of Fish Species in Aquaculture.International journal of molecular sciences · 2024Review
- Exploring opportunities of Artificial Intelligence in aquaculture to meet increasing food demand.Food chemistry: X · 2024Review
- Review
- Genetic improvement and genomic resources of important cyprinid species: status and future perspectives for sustainable production.Frontiers in genetics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scientists have discovered many ways to treat bacteria, viruses, and parasites in aquaculture; however, there is still an impossibility in finding a permanent solution for all types of diseases. In that case, the CRISPR-Cas genome-editing technique can be the potential solution to preventing diseases for aquaculture sustainability. CRISPR-Cas is cheaper, easier, and more precise than the other existing genome-editing technologies and can be used as a new disease treatment tool to solve the far-reaching challenges in aquaculture. This technique may now be employed in novel ways, such as modifying a single nucleotide base or tagging a location in the DNA with a fluorescent protein. This review paper provides an informative discussion on adopting CRISPR technology in aquaculture disease management. Starting with the basic knowledge of CRISPR technology and phages, this study highlights the development of RNA-guided immunity to combat the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.